Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva L, Estruch BC, Merino JAG, Meca-Lallana V, Río J, Rodríguez-Antigüedad A, Agüera E, Ara JR, Luque AA, Garcia CA, Blanco Y, Castillo-Triviño T, Costa-Frossard L, González Platas M, Pascual LL, Llaneza-González M, Ginés MLM, Matías-Guiu J, Meca-Lallana JE, Bilbao MM, Sempere AP, Romero-Pinel L, Saiz A, Moral E. Brieva L, et al. Among authors: gines mlm. Mult Scler Relat Disord. 2022 Jul;63:103805. doi: 10.1016/j.msard.2022.103805. Epub 2022 Apr 12. Mult Scler Relat Disord. 2022. PMID: 35512501 Review.
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
Pilo de la Fuente B, Sabín J, Galán V, Thuissard I, Sainz de la Maza S, Costa-Frossard L, Gómez-Moreno M, Díaz-Díaz J, Oreja-Guevara C, Lozano-Ros A, García-Domínguez JM, Borrego L, Ayuso L, Castro A, Sánchez P, Meca-Lallana V, Muñoz C, Casanova I, López de Silanes C, Martín H, Rodríguez-García E, Andreu-Vázquez C, Blasco R, García-Merino JA, Aladro Y; Dimethyl Fumarate Study Group. Pilo de la Fuente B, et al. CNS Drugs. 2020 Dec;34(12):1275-1286. doi: 10.1007/s40263-020-00775-9. Epub 2020 Nov 23. CNS Drugs. 2020. PMID: 33226562